Thalidomide–dexamethasone as up‐front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low‐dose warfarin
Michela Cini(Baxter (Austria)), Michèle Cavo(Unknown), Patrizia Tosi(Azienda Unità Sanitaria Locale Della Romagna), Alessandro Gozzetti(University of Siena), Paola Tacchetti(Istituto di Ematologia di Bologna), Elena Zamagni(Istituti di Ricovero e Cura a Carattere Scientifico), Francesca Patriarca(Ospedale Santa Maria della Misericordia di Udine), Lucio Catalano(University of Naples Federico II), Lelia Valdré(Baxter (Austria)), Luciano Masini(Casa di Cura Villa Garda), Cristina Legnani(University of Bologna), Gualtiero Palareti(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola)
Cited by 34
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Oral Anticoagulant Therapy
|CHEST Journal|2012|1.5k